Marc de Garidel

CEO at Abivax

Speaker

Marc joined Abivax in May 2023. Prior to that, he led the successful sale of CinCor Pharma for up to USD 1.8B, subject to the achievement of certain milestones, to AstraZeneca in February 2023, after joining the firm in July 2021. Marc also led the sale of Corvidia Therapeutics in August 2020 to Novo Nordisk for USD 2.1B in total consideration after having joined the company as CEO in April 2018. He was the CEO of Ipsen from November 2010 to July 2016, overseeing the development of its US presence. Prior to that, Marc worked for Amgen and Eli Lilly in jobs of increasing responsibilities in various international markets. He has served as Chairman of the Board of Ipsen since 2016 and has been a member of the board of directors of Claris Bio since 2020. Marc has a degree in civil engineering from the Ecole des Travaux Publics in Paris, a master’s degree in international management (MIM) from Thunderbird School of Global Management, and an executive MBA from Harvard Business School.